Ozmosi | Sacituzumab govitecan Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Sacituzumab govitecan

Alternative Names: sacituzumab govitecan, immu-132, trodelvy, sacituzumab govitecan-hziy
Clinical Status: Active
Latest Update: 2026-01-12
Latest Update Note: News Article

Product Description

Sacituzumab govitecan-hziy is a type of targeted therapy drug called an antibody-drug conjugate. It consists of a monoclonal antibody linked to a toxic drug called SN-38 that binds to a protein on the surface of some cancer cells. The linked drug enters these cancer cells and blocks an enzyme called topoisomerase I. This damages the DNA of the cancer cells and kills them. (Sourced from: https://www.cancer.gov/about-cancer/treatment/drugs/sacituzumabgovitecan-hziy)

Mechanisms of Action: TROP2 Inhibitor

Novel Mechanism: No

Modality: Antibody Drug Conjugate

Route of Administration: Intravenous

FDA Designation: Accelerated Approval - Breast Cancer|Oncology Solid Tumor Unspecified|Triple Negative Breast Cancer
Accelerated Approval - Oncology Solid Tumor Unspecified|Transitional Cell Carcinoma
Breakthrough Therapy - Small Cell Lung Cancer
Fast Track - Oncology Solid Tumor Unspecified|Transitional Cell Carcinoma
Orphan Drug - Breast Cancer|Oncology Solid Tumor Unspecified|Triple Negative Breast Cancer
Orphan Drug - Glioblastoma *

Approval Status: Approved

Approved Countries: Australia | Austria | Belgium | Brazil | Canada | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Israel | Italy | Latvia | Lithuania | Luxembourg | Netherlands | Norway | Poland | Portugal | Romania | Saudi Arabia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Turkey | United Arab Emirates | United Kingdom | United States

Approved Indications: None

Known Adverse Events: None

Company: Gilead Sciences
Company Location: Western America
Company CEO: Daniel P. O’Day
Additional Commercial Interests: Everest Medicines

Clinical Description

Map of Global Clinical Trials for Sacituzumab govitecan

Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Croatia, Czech Republic, France, Georgia, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Malaysia, Mexico, Netherlands, Poland, Portugal, Puerto Rico, Romania, Singapore, Slovakia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 97

Recent & Upcoming Milestones

  • Clinical Outcomes Reported - Gilead Sciences presented P3 Breast Cancer results on 2025-11-07 for Sacituzumab govitecan
  • Clinical Outcomes Reported - Gilead Sciences presented P3 Triple Negative Breast Cancer results on 2025-10-19 for Sacituzumab govitecan
  • Clinical Outcomes Reported - Gilead Sciences presented P3 Triple Negative Breast Cancer results on 2025-05-23 for Sacituzumab govitecan

Highest Development Phases

Phase 3: Breast Cancer|Endometrial Cancer|Non-Small-Cell Lung Cancer|Small Cell Lung Cancer|Transitional Cell Carcinoma|Triple Negative Breast Cancer

Phase 2: Adenocarcinoma|Alopecia|Anaplastic Thyroid Carcinoma|Bladder Cancer|Brain Cancer|Cervical Cancer|Esophageal Cancer|Gastrointestinal Cancer|Head and Neck Cancer|Laryngeal Cancer|Male Breast Cancer|Mesothelioma|Mouth Cancer|Muscle Cancer|Oncology Solid Tumor Unspecified|Oropharyngeal Cancer|Ovarian Cancer|Prostate Cancer|Renal Cell Carcinoma|Salivary Gland Cancer|Salivary Gland Diseases|Squamous Cell Carcinoma|Thymoma|Thyroid Cancer|Uterine Cancer

Phase 1: Biliary Tract Cancer|Colorectal Cancer|Liver Failure|Pancreatic Cancer

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT06065371

HFH-23-03

P1

Recruiting

Colorectal Cancer|Gastrointestinal Cancer|Esophageal Cancer|Biliary Tract Cancer|Pancreatic Cancer

2026-12-01

50%

2025-12-20

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments

NCT04617522

IMMU-132-15

P1

Recruiting

Liver Failure

2026-12-01

50%

2024-07-27

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments

NCT05833867

RAD-SG

P1

Recruiting

Transitional Cell Carcinoma|Bladder Cancer

2025-12-01

50%

2025-01-03

Primary Completion Date|Primary Endpoints|Start Date|Treatments

NCT06923826

TROP2

P2

Recruiting

Thyroid Cancer|Salivary Gland Diseases|Salivary Gland Cancer

2030-04-01

12%

2025-07-26

Primary Endpoints|Start Date|Treatments|Trial Status

NCT06477419

NCT06477419

P2

Recruiting

Mesothelioma

2029-06-21

12%

2024-06-28

Primary Endpoints|Treatments

NCT05884320

NCI-2023-04260

P2

Recruiting

Salivary Gland Cancer

2028-07-31

12%

2026-01-10

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments

NCT07063212

NCT07063212

P2

Recruiting

Squamous Cell Carcinoma|Oropharyngeal Cancer|Head and Neck Cancer|Laryngeal Cancer|Mouth Cancer

2028-01-02

12%

2025-07-15

Primary Endpoints|Treatments

NCT06235216

SETHY

P2

Recruiting

Thyroid Cancer|Anaplastic Thyroid Carcinoma

2027-12-01

64%

2024-09-26

Primary Endpoints|Start Date|Treatments|Trial Status

NCT04724018

NCT04724018

P2

Recruiting

Bladder Cancer|Renal Cell Carcinoma|Transitional Cell Carcinoma

2027-02-01

12%

2025-11-05

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status

NCT06682728

UCI 23-59

P2

Recruiting

Bladder Cancer|Muscle Cancer|Transitional Cell Carcinoma

2026-12-01

12%

2024-11-22

Primary Endpoints|Treatments|Trial Status

NCT06100874

SATEEN

P2

Recruiting

Male Breast Cancer

2026-11-30

12%

2024-03-16

Primary Endpoints|Start Date|Treatments

NCT06329869

SG-ESCC

P2

Recruiting

Esophageal Cancer|Squamous Cell Carcinoma

2026-11-01

12%

2024-12-03

Primary Endpoints|Start Date|Trial Status

NCT06401824

CO-NL-979-6888

P2

Recruiting

Brain Cancer|Non-Small-Cell Lung Cancer|Small Cell Lung Cancer

2026-11-01

12%

2025-05-07

Primary Endpoints|Start Date|Treatments|Trial Status

NCT06028932

NCT06028932

P2

Active, not recruiting

Ovarian Cancer

2026-11-01

2%

2025-09-16

NCT05119907

EVER-132-003

P2

Active, not recruiting

Oncology Solid Tumor Unspecified

2026-10-01

12%

2025-11-18

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments

NCT04986579

NCT04986579

P2

Recruiting

Alopecia|Breast Cancer

2026-06-01

75%

2024-06-28

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments

NCT05838521

NCT05838521

P2

Recruiting

Uterine Cancer|Cervical Cancer

2026-06-01

12%

2024-01-12

Primary Endpoints|Start Date

NCT06248515

STUDY00007501

P2

Recruiting

Thymoma

2026-04-01

12%

2024-05-30

Primary Completion Date|Primary Endpoints|Start Date

NCT04468061

Saci-IO TNBC

P2

Recruiting

Triple Negative Breast Cancer

2026-04-01

12%

2024-04-17

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments

NCT05186974

EVOKE-02

P2

Active, not recruiting

Non-Small-Cell Lung Cancer

2026-02-01

2%

2024-08-24

Primary Completion Date|Primary Endpoints|Treatments

NCT06123468

SAGA

P2

Completed

Gastrointestinal Cancer|Adenocarcinoma|Esophageal Cancer

2026-01-07

66%

2026-01-09

Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status

NCT04251416

NCT04251416

P2

Active, not recruiting

Endometrial Cancer

2025-12-01

12%

2025-08-14

Primary Endpoints|Treatments|Trial Status

NCT03725761

UW18043

P2

Active, not recruiting

Prostate Cancer

2024-04-18

12%

2025-04-26

NCT04639986

EVER-132-002

P3

Active, not recruiting

Breast Cancer

2025-12-01

79%

2024-06-28

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments

2024-512279-10-00

GS-US-595-6184

P3

Recruiting

Triple Negative Breast Cancer

2033-05-20

2025-05-02

Treatments